Medidata Rave Selected by Roche as Enterprise-Wide EDC System
NEW YORK – July 1, 2009 –
Headquartered in Basel, Switzerland, Roche is one of the world’s leading global health care companies, focusing on providing medicines and diagnostic tools for devastating diseases worldwide. Roche will deploy Medidata Rave in clinical trials as its core enterprise-wide EDC system in a phased, multi-year approach across its five disease biology areas (oncology, inflammation, virology, metabolism and central nervous system), beginning with data collection for early stage, exploratory trials and ultimately encompassing all phases of development, through registration.
Medidata Rave has become a leader in solutions for the capture, management and reporting of clinical data on the basis of its usability, flexibility, scalability and accessibility. Data managers, investigators, monitors and other clinical team members use Rave to work collaboratively through its Web-based, easy-to-learn, easy-to-use interfaces. Rave’s robust data management tools built directly into the EDC system broaden capabilities, such as management of mid-study changes, and provide a single platform that facilitates broad, global efficiencies across multiple trials, multiple languages and multiple development programs.
“Roche’s enterprise-level investment in Medidata Rave as the foundation of its global drug development process is further proof that sponsors are looking for EDC solutions that not only offer access to data that will drive critical clinical research decisions across all phases, but also provide key efficiencies for all members of the research team,” said Tarek Sherif, CEO, Medidata Solutions. “We are proud that Medidata Rave will be playing a key role in Roche’s strategy to provide treatments and diagnostic tools that enable improvements in the health, quality of life and survival of patients worldwide.”
For more information on Medidata Rave visit:
About Medidata Solutions Worldwide
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025